| |
HR (95% CI)
|
P value
|
|---|
|
Overall survival
|
|
Disease stage
|
1.45 (1.01–2.06)
|
0.041
|
|
T stage
|
1.36 (0.87–2.13)
|
0.184
|
|
N stage
|
1.48 (1.06–2.05)
|
0.021
|
|
Max. tumor size
|
1.01 (1.00–1.03)
|
0.031
|
|
Concurrent chemotherapy
|
1.50 (0.66–3.42)
|
0.330
|
|
Age
|
1.02 (0.99–1.06)
|
0.217
|
|
Sex
|
1.27 (0.60–2.70)
|
0.532
|
|
Disease-free survival
|
|
Disease stage
|
1.56 (1.03–2.38)
|
0.037
|
|
T stage
|
1.05 (0.64–1.78)
|
0.868
|
|
N stage
|
1.66 (1.14–2.42)
|
0.009
|
|
Max. tumor size
|
1.00 (0.98–1.02)
|
0.937
|
|
Concurrent chemotherapy
|
1.17 (0.47–2.93)
|
0.739
|
|
Age
|
1.01 (0.97–1.06)
|
0.509
|
|
Sex
|
1.66 (0.69–3.98)
|
0.259
|
|
Locoregional control
|
|
Disease stage
|
1.62 (1.04–2.53)
|
0.033
|
|
T stage
|
1.17 (0.67–2.03)
|
0.586
|
|
N stage
|
1.68 (1.13–2.51)
|
0.010
|
|
Max. tumor size
|
1.00 (0.98–1.02)
|
0.725
|
|
Concurrent chemotherapy
|
1.26 (0.47–3.35)
|
0.650
|
|
Age
|
1.01 (0.97–1.06)
|
0.608
|
|
Sex
|
1.67 (0.66–4.20)
|
0.278
|
|
Colostomy free survival
|
|
Disease stage
|
1.48 (0.95–2.30)
|
0.082
|
|
T stage
|
1.30 (0.74–2.30)
|
0.358
|
|
N stage
|
1.62 (1.07–2.46)
|
0.022
|
|
Max. tumor size
|
1.01 (0.99–1.03)
|
0.227
|
|
Concurrent chemotherapy
|
1.26 (0.47–3.36)
|
0.644
|
|
Age
|
0.99 (0.95–1.03)
|
0.533
|
|
Sex
|
1.04 (0.40–2.69)
|
0.931
|
- HR hazard ratio, CI confidence interval
